Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase (14C)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02640755
Recruitment Status : Completed
First Posted : December 29, 2015
Results First Posted : April 22, 2019
Last Update Posted : April 22, 2019
Sponsor:
Collaborator:
Quintiles, Inc.
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:

This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts:

  1. Single Dose Period - will characterise the absorption, metabolism, excretion and pharmacokinetics of a single oral dose of [14C]AZD2014 from the body
  2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour activity of multiple doses of AZD2014 when given as a monotherapy or given in combination with paclitaxel or fulvestrant.

Condition or disease Intervention/treatment Phase
Solid Malignancies Drug: [14C]AZD2014 Drug: Multiple dose AZD2014 Drug: Fulvestrant Drug: Paclitaxel Phase 1

Detailed Description:

This is a Phase I, open label, single centre, non-randomised study in patients with advanced solid malignancies that is refractory or resistant to standard treatment or where no suitable effective standard treatment exists or for whom paclitaxel or fulvestrant are appropriate treatment choices. The study will be divided in two parts:

  1. Single Dose Period - will enrol up to 6 evaluable patients to characterise the absorption, metabolism, excretion and pharmacokinetics of a single radiolabelled [14C] oral dose of 125mg AZD2014 via residential intensive PK sampling over 8 days. An evaluable patient is defined as patient who does not vomit within 2 hours post dose and who has completed the scheduled PK sampling.
  2. Multiple Dose Period - patients who have completed the Single Dose Period may continue to receive treatment as outpatients. Patients will be allocated to different treatment regimes as decided between Investigator and patient on a risk / benefit basis. From Day 1, Cycle 1, non-radiolabelled AZD2014 treatment will be administered as oral tablets to patients, either as:

i. 50mg BD monotherapy ii. 125mg BD taken on first 2 days of treatment each week in combination with 500mg intramuscular fulvestrant on Day 1, Cycle 1, Day 15, Cycle 1; Day 1, Cycle 2, then Day 1 of each monthly cycle thereafter iii. 50mg BD taken on first 3 days of treatment each week for 6 weeks in combination with a single weekly paclitaxel infusion (80mg/m2 ) followed by a one week break from treatment where no AZD2014 or paclitaxel will be given. This 7 week schedule composes one cycle of treatment. Patients will be given up to 6 cycles of paclitaxel, although additional cycles of paclitaxel may be given if deemed appropriate by the Investigator.

Radiolabelled AZD2014 will be administered to fasted patients (i.e. no food 2 hours before and 1 hour after each dose). Non-radiolabelled AZD2014 will be administered either under fasted or non-fasted conditions. The safety and tolerability and anti-tumour activity of AZD2014 and combination with paclitaxel or fulvestrant will be evaluated in all enrolled patients respectively using conventional safety parameters, AEs/SAEs and RECIST 1.1.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies
Actual Study Start Date : January 28, 2016
Actual Primary Completion Date : December 21, 2016
Actual Study Completion Date : July 6, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: [14C]AZD2014 followed by AZD2014 Monotherapy
Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
Drug: [14C]AZD2014
Radiolabelled dual TORC1/TORC2 inhibitor

Drug: Multiple dose AZD2014
Dual TORC1/TORC2 inhibitor

Experimental: [14C]AZD2014 followed by AZD2014 + Fulvestrant
Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
Drug: [14C]AZD2014
Radiolabelled dual TORC1/TORC2 inhibitor

Drug: Multiple dose AZD2014
Dual TORC1/TORC2 inhibitor

Drug: Fulvestrant
Hormonal Agent

Experimental: [14C]AZD2014 followed by AZD2014 + Paclitaxel
Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
Drug: [14C]AZD2014
Radiolabelled dual TORC1/TORC2 inhibitor

Drug: Multiple dose AZD2014
Dual TORC1/TORC2 inhibitor

Drug: Paclitaxel
Taxane




Primary Outcome Measures :
  1. Total Radioactivity in Plasma Following Administration of [14C]-AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32 and 48 hours (h) post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean concentrations of total radioactivity in plasma collected from each patient who received a single oral dose of 125 mg [14C]-AZD2014 are presented for time points of plasma sampling up to 48 hours post-dose. Geometric mean concentrations were not quantifiable after 48 hours. The total [14C] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

  2. AZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean concentrations of AZD2014 in plasma collected from each patient who received a single oral dose of 125 mg [14C]-AZD2014 are presented for time points of plasma sampling up to 24 hours post-dose. Geometric mean concentrations were not quantifiable after 24 hours.

  3. Total Radioactivity Concentrations in Saliva Following Administration of [14C]-AZD2014 [ Time Frame: Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean concentrations of total radioactivity in saliva collected from each patient who received a single oral dose of 125 mg [14C]-AZD2014 are presented for time points of saliva collection up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total [14C] radioactivity in saliva was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

  4. AZD2014 Concentrations in Saliva Following Administration of [14C]-AZD2014 [ Time Frame: Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean concentrations of AZD2014 in saliva collected from each patient who received a single oral dose of 125 mg [14C]-AZD2014 are presented for time points of plasma sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours.

  5. Total Radioactivity Concentrations in Blood Following Administration of [14C]-AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean concentrations of total radioactivity in blood collected from each patient who received a single oral dose of 125 mg [14C]-AZD2014 are presented for time points of blood sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total [14C] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

  6. Cumulative Percentage of [14C]-AZD2014 Recovered by Day 8 [ Time Frame: From pre-dose Day 1 to Day 8 of the Single Dose Period. ]

    The mean cumulative percentage of [14C]-AZD2014 dose recovered as total radioactivity by the end of the Single Dose Period (Day 1 - 8) is presented. The total [14C] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

    Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.


  7. Maximum Observed Concentration (Cmax) of AZD2014 in Plasma and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean AZD2014 Cmax values in plasma and saliva following administration of [14C]-AZD2014 on Day 1 are presented.

  8. Time to Maximum Observed Concentration (Tmax) for AZD2014 in Plasma and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    AZD2014 Tmax values for plasma and saliva following administration of [14C]-AZD2014 on Day 1 are presented.

  9. Time to Last Measurable Concentration (t[Last]) for AZD2014 in Plasma and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    AZD2014 t(last) values in plasma and saliva following administration of [14C]-AZD2014 on Day 1 are presented.

  10. Area Under the Plasma Concentration-time Curve (AUC) for AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean AUC for AZD2014 following administration of [14C]-AZD2014 on Day 1 is presented.

  11. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for AZD2014 in Plasma and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean AUC(0-t) values in plasma and saliva for AZD2014 following administration of [14C]-AZD2014 on Day 1 are presented.

  12. Apparent Total Body Clearance (CL/F) of AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean CL/F of AZD2014 in plasma following administration of [14C]-AZD2014 on Day 1 is presented.

  13. Mean Residence Time (MRT) of AZD2014 [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The MRT of AZD2014 in plasma following administration of [14C]-AZD2014 on Day 1 is presented.

  14. Apparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean Vss/F of AZD2014 in plasma following administration of [14C]-AZD2014 on Day 1 is presented.

  15. Terminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean lambda_z of AZD2014 in plasma following administration of [14C]-AZD2014 on Day 1 is presented.

  16. Half-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h ost [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean t1/2(lambda_z) for AZD2014 in plasma following administration of [14C]-AZD2014 on Day 1 is presented.

  17. Cmax for Total [14C] Radioactivity in Whole Blood and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean [14C] radioactivity Cmax values in whole blood and saliva following administration of [14C]-AZD2014 on Day 1 are presented.

  18. Tmax for [14C] Radioactivity in Whole Blood and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    [14C] radioactivity tmax in whole blood and saliva following administration of [14C]-AZD2014 on Day 1 is presented .

  19. T(Last) for [14C] Radioactivity in Whole Blood and Saliva [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean [14C] radioactivity t(last) values in whole blood and saliva following administration of [14C]-AZD2014 on Day 1 are presented.

  20. Ratio of Whole Blood Total Radioactivity to Plasma Total Radioactivity [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose. ]
    The mean ratios of whole blood total radioactivity to plasma total radioactivity are presented for the timepoints of sample collection up to 12 hours post-dose. Geometric mean ratios were not calculated after 12 hours.

  21. Ratio of AZD2014 Concentration to Total Radioactivity Concentration in Saliva [ Time Frame: Saliva was collected at 1, 2, 4, 6, 8 and 10 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    The mean ratios of saliva AZD2014 to saliva radioactivity concentrations are presented for the timepoints of saliva collection up to 10 hours post-dose. Geometric mean ratios were not calculated after 10 hours. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

  22. Fraction of AZD2014 Excreted in Urine as a Percentage of the Dose (fe%[R]) [ Time Frame: Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    Mean fe%(R) values per urine collection period are presented as a percentage of the total [14C]-AZD2014 dose administered on Day 1.

  23. Renal Clearance (CL[R]) of AZD2014 From Plasma. [ Time Frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period. ]
    CL(R) of AZD2014 from plasma up to 168 h post-dose.

  24. Cumulative Percentage of Total [14C] Radioactivity Excreted in Urine as a Percentage of the Dose (fe Cum%[R]) [ Time Frame: Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period. ]

    fe cum%(R) by the end of each collection period is presented following administration of [14C]-AZD2014.

    Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.


  25. Cumulative Percentage of Total [14C] Radioactivity Excreted in Stool as a Percentage of the Dose (fe Cum%[f]) [ Time Frame: Stool was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period. ]

    fe cum%(f) by the end of each collection period is presented following administration of [14C]-AZD2014.

    Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.



Secondary Outcome Measures :
  1. Number of AEs Experienced by Patients. [ Time Frame: From Day 1 of the Single Dose Period to 30 days after the last dose of AZD2014 administered in the Multiple Dose Period. ]
    AEs (including serious AEs [SAEs]) were collected from the time of informed consent (Visit 1) and throughout the study, including the 30-day follow-up. The numbers of patients experiencing any AEs and SAEs, causally related AEs and SAEs, and SAEs which were fatal are presented.

  2. Best Overall Response (BOR) Assessment [ Time Frame: RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period. ]

    Anti-tumour activity through assessment of BOR. BOR was defined for each patient as follows according to the RECIST 1.1 criteria:

    Complete Response (CR): Disappearance of all target lesions since baseline. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions.

    Stable Disease (SD): Any cases that do not qualify for either PR or progressive disease (PD).

    PD: At least a 20% increase in the sum of the diameters of target lesions. BOR for each patient was determined as the best response recorded from the day study treatment started until progression or until the last evaluable RECIST tumour assessment in the absence of progression.


  3. Best Percentage Change in Tumour Size From Baseline [ Time Frame: RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period. ]
    Assessment of anti-tumour activity through measurement of tumour lesions. Tumour size was defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed, written & dated informed consent prior to any study specific procedures.
  • Male or female patients aged at least 18 years.
  • Have a body mass index (BMI) ≥18 kg/m2 and ≤35 kg/m2 & weigh at least 50 kg.
  • Histological or cytological confirmation of a solid malignant tumour that is refractory or resistant to standard therapies or for which no suitable effective standard therapies exist. SqNSCLC patients are excluded from the 50mg BD AZD2014 in combination with paclitaxel cohort.
  • For patients intending to enter combination therapy with fulvestrant or paclitaxel, this should be deemed as an appropriate treatment option by Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with no deterioration over previous 2 weeks & minimum life expectancy of 12 weeks.
  • At least one lesion (measurable and/or non-measurable but evaluable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray & is suitable for repeated assessment
  • Able & willing to stay in hospital for approximately 9 days
  • Females should be using adequate contraceptive measures, should not be breast feeding & must have negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
  • Male patients should be surgically sterile or willing to use barrier contraception ie, condoms and spermicide &refrain from donating sperm from start of dosing until 16 weeks after discontinuing of study treatment.
  • Regular bowel movements (ie, on average production of at least 1 stool per day)

Exclusion Criteria:

  • Involvement in planning and/or conduct of the study
  • Previous enrolment in present study
  • Another study with an investigational product in last 28 days
  • Chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents & any investigational agents within 21 days of starting treatment (not including palliative radiotherapy at focal sites), or corticosteroids within 14 days
  • Major surgery within 4 weeks, or minor surgery within 14 days
  • Exposure to strong and moderate inhibitors or inducers of cytochrome P450 (CYP) 3A4/5, P-glycoprotein (Pgp) (multidrug resistance gene [MDR1]), and breast cancer resistance protein (BCRP), if taken within stated washout periods
  • Exposure to specific substrates of the drug organic anion-transporting polypeptide (OATP)1B1, OATP1B3, organic anion transporting polypeptide (OCT)1 and OCT2 within appropriate washout period
  • Any haemopoietic growth factors (eg, filgrastim [granulocyte colony-stimulating factor; G-CSF], sargramostim [granulocyte-macrophage colony-stimulating factor; GM-CSF]) within 14 days prior to receiving study treatment
  • Previous treatment with AZD2014 or AZD8055
  • Patients who have received fulvestrant within 3 months
  • With exception of alopecia, any unresolved toxicities chemotherapy/radiotherapy should be no greater than CTCAE grade 1
  • Participated in another absorption, distribution, metabolism and excretion study within 1 year
  • Spinal cord compression and/or brain metastases unless asymptomatic or treated & stable off steroids for at least 4 weeks
  • Severe or uncontrolled systemic diseases (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, active bleeding diatheses or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
  • Recent history of drug abuse or alcohol abuse
  • Patients who have undergone any of the following procedures or experienced conditions currently or in preceding 12 months:

    • Coronary artery bypass graft
    • Angioplasty
    • Vascular stent
    • Myocardial infarction
    • Angina pectoris
    • Congestive heart failure New York Heart Association Grade 2
    • Ventricular arrhythmias requiring continuous therapy
    • Uncontrolled supraventricular arrhythmias including atrial fibrillation
    • Haemorrhagic or thrombotic stroke, including transient ischaemic attacks or other central nervous system bleeding
  • Abnormal echocardiogram at baseline (left ventricular ejection fraction [LVEF] <55% and shortening fraction [SF] <15%)
  • Torsades de Pointes either currently or within 12 months
  • Mean resting QTcF ≥470 ms
  • Medications known to prolong QT interval, or that increase the risk of QTc prolongation or arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of either long QT syndrome), or unexplained sudden death under 40 years of age
  • Laboratory values as listed below:

    • Absolute neutrophil count <1.5x109/L
    • Platelet count <100x109/L
    • Haemoglobin <90 g/L
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or >5xULN in the presence of liver metastases
    • Total bilirubin >1.5xULN if no demonstrable liver metastases or >3xULN in the presence of liver metastases
    • Serum creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation), confirmation of creatinine clearance is only required when creatinine is >1.5xULN
    • Clinically relevant and treatment resistant abnormalities in potassium, sodium, calcium (corrected for plasma albumin) or magnesium
  • Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis
  • Abnormal fasting glucose >126 mg/dL (>7 mmol/L)
  • Patients with diabetes Type 1 or uncontrolled Type 2 (glycosylated haemoglobin [HbA1c] >8% [64 mmol/mol] assessed locally)
  • Current refractory nausea and vomiting, chronic gastrointestinal disease or inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
  • History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
  • Judgment that patient is unsuitable to participate in study and unlikely to comply with study procedures, restrictions & requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02640755


Locations
Layout table for location information
United Kingdom
Research Site
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
AstraZeneca
Quintiles, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Emma Dean, MD The Christie NHS Foundation Trust

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02640755     History of Changes
Other Study ID Numbers: D2270C00015
2015-000198-11 ( EudraCT Number )
First Posted: December 29, 2015    Key Record Dates
Results First Posted: April 22, 2019
Last Update Posted: April 22, 2019
Last Verified: January 2019
Keywords provided by AstraZeneca:
Radiolabelled
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Fulvestrant
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs